Completed PHASE3 INTERVENTIONAL NCT00135876

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)

Sponsor: Ontario Clinical Oncology Group (OCOG)

Conditions Brain Tumors Venous Thromboembolism

Interventions dalteparin

Updated 5 times since 2017 Last updated: Apr 25, 2007 Started: Oct 31, 2002 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Brain Tumors and Venous Thromboembolism and is currently completed. Ontario Clinical Oncology Group (OCOG) leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ontario Clinical Oncology Group (OCOG)
Pfizer

Data source: Ontario Clinical Oncology Group (OCOG)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bergamo, Italy , Detroit, United States , Edmonton, Canada , Evanston, United States , Halifax, Canada , Kogarah, Australia , Nedlands, Australia , Ottawa, Canada , Perth, Australia , Perugia, Italy and 3 more locations